Articles tagged "HLA antigens"

2020 American Transplant Congress
Rare HLA DRB1*10-DQB1*06 Linkage Disequilibrium: A Case Study That Emphasizes the Need of Having an HLA Toolbox
S. Dionne, L. Santiago, S. Shetty
VRL-Eurofins, Centennial, CO
*Purpose: This case study highlights the need to use different tools to derive and validate HLA typing results especially in instances of rare typing.*Methods: Low/intermediate…
2020 American Transplant Congress
HLA-DQ Plays an Important Role in Graft Survival in African American Transplant Recipients
L. M. Rebellato¹, W. Irish², D. Leeser², J. Tuttle², C. E. Haisch²
¹Pathology, The Brody School of Medicine at ECU, Greenville, NC, ²Surgery, The Brody School of Medicine at ECU, Greenville, NC
*Purpose: Our kidney transplant (KTx) program serves a medically underserved and racially diverse area of a southern state. The purpose of this study was to…
2020 American Transplant Congress
Cardiac Transplantation is Accompanied by Major T and NK Cell Alterations within the First 24 Hours
J. Iske¹, B. Wiegmann², K. Ludwig¹, N. Ledwoch¹, E. Chichelnitskiy¹, J. F. Kühne¹, A. Hitz¹, R. Bellmàs-Sanz¹, K. Daemen¹, J. Keil¹, F. Ius², S. Rochas², A. Knoefel², A. Haverich², G. Warnecke², C. S. Falk¹
¹Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, ²Division of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
*Purpose: Allogeneic heart transplantation (HTx) displays the only curative approach for terminal heart insufficiency while acute allograft rejection remains a major complication. However, early kinetics…
2020 American Transplant Congress
Risk Epitope Mismatch Does Not Predict Short Term Heart Transplant Outcomes
Y. Moayedi¹, J. McCaughan², E. Henricksen³, B. Mueller⁴, S. Fan⁴, H. J. Ross¹, K. Khush⁵, B. M. Zhang⁶, J. Teuteberg⁵
¹Cardiology, Ted Rogers Centre for Heart Research, University Health Network, University of Toronto, Toronto, ON, Canada, ²HLA Lab, Belfast Trust, Belfast, Ireland, ³Pharmacy, Stanford Healthcare, Stanford, CA, ⁴Computational Program TRCHR, Ted Rogers Centre for Heart Research, University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Cardiology, Stanford University, Stanford, CA, ⁶HLA Lab, Stanford University, Stanford, CA
*Purpose: Heart transplantation (HT) remains the gold standard treatment for end-stage heart failure. Despite significant improvements in short-term outcomes, the median survival after heart transplantation…
2020 American Transplant Congress
Low HLA Class I Epitope Mismatch Associated with Improved Pancreas Graft Survival in Simultaneous Pancreas-Kidney Transplantation
J. M. Ladowski, M. Romine, D. Kloda, C. Young, J. Locke, V. Hauptfeld-Dolejsek, J. Houp
University of Alabama-Birmingham, Birmingham, AL
*Purpose: Antibody-mediated rejection remains the principal cause of allotransplant graft failure. Human leukocyte antigen (HLA) matching between donor and recipients significantly reduces the risk of…
2019 American Transplant Congress
Can Imputation of HLA Allele Level Typing Be Used Clinically in a Multiethnic Population?
R. M. Engen¹, A. M. Jedraszko¹, A. Tambur²
¹Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, ²Northwestern University, Chicago, IL
*Purpose: Assignment of eplets in transplantation for the purpose of matching or risk stratification requires high-resolution HLA typing, which is not readily available. Computer algorithms…
2019 American Transplant Congress
EBV Latent Proteins Encode for Peptides That Prevent Natural Killer Cell Inhibition
B. Mbiribindi¹, J. K. Pena¹, O. Hatton², C. Romero Moreno¹, C. O. Esquivel¹, O. M. Martinez¹, S. M. Krams¹
¹Department of Surgery/ Division of Abdominal Transplant, Stanford University - School of Medicine, Stanford, CA, ²Department of Molecular Biology, Colorado College, Colorado Springs, CO
*Purpose: Epstein-Barr virus (EBV) infects more than 90% of adults worldwide and is associated with several malignancies, including post-transplant lymphoproliferative disorder (PTLD). Although EBV infection…
2018 American Transplant Congress
Determining the Relative Immunogenicity of HLA Mismatches with Calcineurin Inhibitor Immunosuppression: An Analysis of the BENEFIT and BENEFIT-EXT Renal Transplant Cohort
V. Jucaud,¹ M. Roberts,² H. Gebel,³ R. Bray,³ M. Everly.¹
¹Terasaki Research Institute, Los Angeles, CA; ²Immunology Biomarker Group, Bristol-Myers Squibb, Princeton, NJ; ³Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.
We studied the relative immunogenicity of HLA-A, -B, -C, -DR and -DQ MM (serological) in a cohort of 291 kidney transplant patients from the BENEFIT…
2018 American Transplant Congress
High Frequency of HLA-DQ De Novo Donor Specific Antibodies is Independent of the Number of Mismatches in Heart Transplant
X. Zhang,¹ E. Kransdorf,² J. Patel,² J. Kobashigawa.²
¹HLA and Immunogenetics Laboratory/ Comprehensive Transplant Center, Cedars-Sinai Health Systems, Los Angeles, CA; ²Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA.
Aim: Development of de novo donor specific antibodies (DSA) after heart transplant is associated with an increased risk of allograft failure. The aim of this…
2018 American Transplant Congress
Not All HLA Mismatches Are Equal: Determining the Relative De Novo DSA Induction Capacity of HLA Mismatches
V. Jucaud,¹ L. Rebellato,² K. Briley,² A. Maldonado,³ C. Haisch,² P. Bolin,² S. Kendrick,⁴ H. Jones,⁴ K. McLawhorn,⁴ D. Leeser,² M. Everly.¹
¹Terasaki Research Institute, Los Angeles, CA; ²East Carolina University, Greenville, NC; ³Vidant Medical Center, Greenville, NC; ⁴Eastern Nephrology Associates, Greenville, NC.
We studied the immunogenicity, defined as the development of de novo DSA (dnDSA), of HLA-A, -B, -DR and -DQ MM (serological) in a cohort of…